My group’s work focuses on the role of the tumour suppressor protein LIMD1 and its family members Ajuba and WTIP and how their deregulation in normal tissue contributes to the development of lung, renal and breast cancer.
We study the role of growth factor receptor signalling and intracellular trafficking (movement inside cells) in tumour growth and metastasis in the view of improving cancer therapy.
My lab aims to understand the alterations in metabolism that take place in cancer and investigate whether extrinsic factors, such as diet, influence cancer metabolism and disease trajectory. We then want to uncover whether these dependencies can be exploited therapeutically.
My research projects involve identifying tumour suppressors involved in regulating the hypoxic response and metabolic stress, with the aim to identify novel targeted therapies against these.
We are investigating the metabolic dependencies of cancer cells under biologically relevant conditions, such as nutrient stress, in a biomarker-specific manner. I use metabolomics, proteomics and other cutting-edge platforms to dissect the metabolic architecture of cancer models that harbour alterations in tumour suppressors that drive disease trajectory and treatment response.
I am interested in cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses.
My research focuses on exploring why ASS1 is differently expressed in human cancers and how this information may be transferred for anticancer therapy.
I am studying how the tumour suppressor gene LIMD1 functions in the microRNA pathway, a gene regulatory pathway that is often dysregulated in cancer.